NCT07566494 is a Phase 1 clinical trial of VAS-101 in Sickle Cell Disease, Hemolytic Anemia, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Who is sponsoring NCT07566494?

NCT07566494 is sponsored by National Heart, Lung, and Blood Institute (NHLBI).

What drugs are being tested in NCT07566494?

Interventions in NCT07566494: VAS-101.

What condition does NCT07566494 study?

NCT07566494 studies Sickle Cell Disease, Hemolytic Anemia.

Is NCT07566494 still recruiting?

NCT07566494 is currently not yet recruiting.

Last reviewed 2026-05-22 · How we verify

NCT07566494

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease

Not yet recruiting Phase 1

What this trial tests

Phase 1 trial testing VAS-101 in Sickle Cell Disease, Hemolytic Anemia in 25 participants. Not yet recruiting.

Timeline

20 May 2026

27 April 2027

Quick facts

Lead sponsor	National Heart, Lung, and Blood Institute (NHLBI)
Phase	Phase 1
Status	Not yet recruiting
Enrollment	25
Start date	20 May 2026
Estimated completion	27 April 2027

Drugs / interventions tested

VAS-101

Conditions studied

Sickle Cell Disease, Hemolytic Anemia — all drugs for Sickle Cell Disease, Hemolytic Anemia →

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Who can join

Eligibility, any sex, with Sickle Cell Disease, Hemolytic Anemia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other National Heart, Lung, and Blood Institute (NHLBI) trials

Trials by the same sponsor.

NCT05372627 — NHLBI-Emory Advanced Cardiac CT Reconstruction · not yet recruiting
NCT07137455 — EDEN Intracardiac Electrogram Recording and Classifying System · NA · enrolling by invitation
NCT06948097 — Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fost · Phase 1 · not yet recruiting
NCT07516379 — GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejecti · not yet recruiting
NCT06280820 — Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART) · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07566494 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Heart, Lung, and Blood Institute (NHLBI)
Last refreshed: recently

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07566494.